TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial

BACKGROUND: TG01 is the first cancer immunotherapy targeting KRAS oncogenic mutations. This study assessed the safety and efficacy of TG01/GM-CSF in patients with resected pancreatic adenocarcinoma. METHODS: Patients with stage I or II pancreatic adenocarcinoma who had undergone surgical resection (...

Descripción completa

Detalles Bibliográficos
Autores principales: Palmer, Daniel H., Valle, Juan W., Ting Ma, Yuk, Faluyi, Olusola, Neoptolemos, John P., Jensen Gjertsen, Trine, Iversen, Berit, Amund Eriksen, Jon, Møller, Anne-Sophie, Aksnes, Anne-Kirsti, Miller, Robert, Dueland, Svein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109101/
https://www.ncbi.nlm.nih.gov/pubmed/32063605
http://dx.doi.org/10.1038/s41416-020-0752-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109101/
https://www.ncbi.nlm.nih.gov/pubmed/32063605
http://dx.doi.org/10.1038/s41416-020-0752-7

Ejemplares similares